Cardiovascular actions of intrahypothalamic injections of atrial natriuretic peptide

Accumulating evidence implicates atrial natriuretic polypeptide (ANP) as a neurotransmitter in brain. The presence and distribution of ANP, its high affinity binding sites, and the messenger RNA of its precursor have been described in the central nervous system. However, the function(s) of ANP in specific brain areas is largely unknown. We have now determined the cardiovascular effects elicited by microinjection of atriopeptin-III (ANP-III) in hypothalamic and preoptic areas in rats. ANP-III (40 pmol) increased heart rate when injected into the anteromedial preoptic nucleus (AMPO), the medial preoptic area (MPA), the periventricular area, and in two regions of the dorsal hypothalamus. Other nuclei within the hypothalamus were unresponsive. The tachycardic effects elicited by AMPO-MPA injection of ANP-III were abolished by adrenalectomy. These data indicate that ANP-III acts at discrete sites to elicit tachycardia and the mechanism of action for at least one brain site appears to be through central pathways which selectively activate the adrenal gland.